Articles On Rhythm Biosciences (ASX:RHY)

Rhythm Biosciences (ASX:RHY) says recent testing has indicated new antibodies for the key lead biomarker used in its ColoSTAT test are able to successfully differentiate between cancer and healthy samples.

Rhythm Biosciences Limited (ASX:RHY) today announced that recent testing has indicated that the new antibodies for the key lead biomarker used in its ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the...

Medical diagnostics company Rhythm Biosciences Ltd (ASX:RHY) has continued to develop its global, low-cost, lifesaving blood test for the detection of colorectal cancer, ColoSTAT®, during the last quarter. Following 13 years of CSIRO resear...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Dimerix Limited (ASX: DXB) Clinical-stage biopharmaceutical company, Dimerix Limited (ASX: DXB) is engaged in developing new therapies for the unmet requirements of the medicine market all over the world. On 26 June 2019, Dimerix announced...

ColoSTAT has the potential to play an important role in reducing morbidity and mortality rates associated with colorectal cancer.

Rewardle Holdings Limited Social media company Rewardle Holdings Limited (ASX: RXH) connects more than 3.2 million members with nearly 5,000 local businesses across Australia. Strategic Partnership with Pepper Leaf Meal Kit Delivery Servic...

Monash Health will be the second clinical trial site with the company expecting to sign further hospitals to join the ColoSTAT trial in coming weeks.

Monash Health has become the second hospital to join the Rhythm Biosciences (ASX:RHY) prospective clinical trial of ColoSTAT - its blood test for the early detection of colorectal cancer.